- Home
- SNAL vs ANTX Comparison
SNAL vs ANTX Comparison
Compare SNAL & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | ANTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 31.2M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SNAL | ANTX |
|---|---|---|
| Price | $0.79 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 21.1K | ★ 132.4K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,330,445.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $50.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $1.00 |
| 52 Week High | $3.42 | $1.55 |
Technical Indicators
Market Signals| Indicator | SNAL | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 49.01 |
| Support Level | $0.78 | $1.14 |
| Resistance Level | $0.83 | $1.28 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 40.56 | 47.16 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.